Nedelcu Andreea, Mocan Teodora, Grapa Cristiana, Mocan Lucian
3rd Surgery Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400158 Cluj-Napoca, Romania.
Nanomedicine Department, Regional Institute of Gastroenterology and Hepatology, Octavian Fodor, 400158 Cluj-Napoca, Romania.
Int J Mol Sci. 2021 Jul 28;22(15):8060. doi: 10.3390/ijms22158060.
Pancreatic cancer (PC), one of the most lethal solid tumors in humans, has a five-year survival rate of only 4%. Surgical treatment is the only accepted therapy with curative intent because the vast majority of these tumors are chemoresistant. Unfortunately, due to the aggressive nature of these tumors, fewer than 20% are resectable when the first symptoms occur. Novel therapies are required to overcome all these therapeutic issues, and the development of active nanocarriers represents an exciting opportunity to improve PC outcomes. The present review focuses on recent advances in the field of nanotechnology with application in PC treatment.
胰腺癌（PC）是人类最致命的实体瘤之一，其五年生存率仅为4%。手术治疗是唯一被认可的具有治愈意图的疗法，因为这些肿瘤中的绝大多数对化疗耐药。不幸的是，由于这些肿瘤具有侵袭性，当出现首发症状时，可切除的肿瘤不到20%。需要新的疗法来克服所有这些治疗问题，而活性纳米载体的开发为改善胰腺癌的治疗效果提供了一个令人兴奋的机会。本综述重点关注纳米技术领域在胰腺癌治疗中的最新进展。
